Background

Since July 13, 2021, a third SARS-CoV-2 vaccine BNT162b2 was approved in Israel to immunocompromised and seniors 60 years of age or older. We aimed to evaluate vaccine's reactogenicity.

Methods

A retrospective cohort, using electronic surveys sent to booster vaccine recipients, during July 20–August 10, 2021.

Results

17,820 participated in the survey, with a response rate of 30.2%. 3195 (17.9%) were immunocompromised. Fatigue, myalgia and fever were the most frequent systemic side effects reported (19.6%, 9.2% and 8.1% respectively among immunocompromised; 21.3%, 9.9% and 9.2% respectively among seniors). 67.3% of immunocompromised and 62% of seniors reported experiencing a better or a similar response to the third dose, compared to the second.

Conclusions

Local and systemic reactions after third BNT162b2 vaccine, reported by immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. These findings may aid promoting confidence among vaccine providers and recipients.

中文翻译：

---

第三种 BNT162b2 mRNA COVID-19 疫苗在免疫功能低下的个体和老年人中的反应原性——一项全国调查

背景

自 2021 年 7 月 13 日以来，以色列批准了第三种 SARS-CoV-2 疫苗 BNT162b2，用于免疫功能低下和 60 岁或以上的老年人。我们旨在评估疫苗的反应原性。

方法

一项回顾性队列研究，在 2021 年 7 月 20 日至 8 月 10 日期间使用发送给加强疫苗接种者的电子调查。

结果

17820人参与了调查，回复率为30.2%。3195 (17.9%) 人免疫功能低下。疲劳、肌痛和发烧是报告的最常见的全身性副作用（免疫功能低下者分别为 19.6%、9.2% 和 8.1%；老年人分别为 21.3%、9.9% 和 9.2%）。与第二剂相比，67.3% 的免疫功能低下者和 62% 的老年人表示对第三剂的反应更好或相似。

结论

免疫功能低下者和老年人报告的第三次 BNT162b2 疫苗接种后的局部和全身反应与之前接种疫苗后观察到的反应相似，并且大多自行解决。这些发现可能有助于提高疫苗提供者和接受者之间的信心。